Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-03-15

AUTHORS

Khurram J Khan, Thomas A Ullman, Alexander C Ford, Maria T Abreu, A Abadir, John K Marshall, Nicholas J Talley, Paul Moayyedi

ABSTRACT

The etiology of inflammatory bowel disease (IBD) is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. Antibiotics have therefore been proposed as a therapy for Crohn's disease (CD) and ulcerative colitis (UC) to induce remission in active disease to prevent relapse. Current data are conflicting and we therefore conducted a systematic review of randomized controlled trials (RCTs) evaluating antibiotics in IBD. Only parallel group RCTs were considered eligible. Studies with adult patients receiving any dose of therapy for at least 7 days and up to 16 weeks for active disease, or at least 6 months of follow-up for preventing relapse in quiescent disease were analyzed. We included any antibiotics alone or in combination using predefined definitions of remission and relapse. Two reviewers independently assessed eligibility and extracted data. The primary outcome was remission or relapse using an intention-to-treat methodology. The data were summarized using relative risk (RR) and pooled using a random effects model. For active CD, there were 10 RCTs involving 1,160 patients. There was a statistically significant effect of antibiotics being superior to placebo (RR of active CD not in remission=0.85; 95% confidence interval (CI)=0.73-0.99, P=0.03). There was moderate heterogeneity between results (I(2)=48%) and a diverse number of antibiotics were tested (anti-tuberculosis therapy, macrolides, fluroquinolones, 5-nitroimidazoles, and rifaximin) either alone or in combination. Rifamycin derivatives either alone or in combination with other antibiotics appeared to have a significant effect at inducing remission in active CD. In perianal CD fistula there were three trials evaluating 123 patients using either ciprofloxacin or metronidazole. There was a statistically significant effect in reducing fistula drainage (RR=0.8; 95% CI=0.66-0.98) with no heterogeneity (I(2)=0%) and an number needed to treat 5 (95% CI=3-20). For quiescent CD, there were 3 RCTs involving 186 patients treated with different antibiotics combinations (all including antimycobacterials) vs. placebo. There was a statistically significant effect in favor of antibiotics vs. placebo (RR of relapse=0.62; 95% CI=0.46-0.84), with no heterogeneity (I(2)=0%). In active UC, there were 9 RCTs with 662 patients and there was a statistically significant benefit for antibiotics inducing remission (RR of UC not in remission=0.64; 95% CI=0.43-0.96). There was moderate heterogeneity (I(2)=69%) and antibiotics used were all different single or combination drugs. Antibiotic therapy may induce remission in active CD and UC, although the diverse number of antibiotics tested means the data are difficult to interpret. This systematic review is a mandate for further trials of antibiotic therapy in IBD. More... »

PAGES

661

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/ajg.2011.72

DOI

http://dx.doi.org/10.1038/ajg.2011.72

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023776266

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21407187


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colitis, Ulcerative", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Crohn Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rifamycins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Secondary Prevention", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "McMaster University Medical Centre, Hamilton, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/grid.411657.0", 
          "name": [
            "McMaster University Medical Centre, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khan", 
        "givenName": "Khurram J", 
        "id": "sg:person.0722775106.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722775106.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Mount Sinai School of Medicine, New York, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.59734.3c", 
          "name": [
            "The Mount Sinai School of Medicine, New York, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ullman", 
        "givenName": "Thomas A", 
        "id": "sg:person.01031655740.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031655740.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK", 
          "id": "http://www.grid.ac/institutes/grid.418161.b", 
          "name": [
            "Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ford", 
        "givenName": "Alexander C", 
        "id": "sg:person.01251421433.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251421433.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Miller School of Medicine, University of Miami, Miami, Florida, USA", 
          "id": "http://www.grid.ac/institutes/grid.26790.3a", 
          "name": [
            "Miller School of Medicine, University of Miami, Miami, Florida, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abreu", 
        "givenName": "Maria T", 
        "id": "sg:person.0606477677.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606477677.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McMaster University Medical Centre, Hamilton, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/grid.411657.0", 
          "name": [
            "McMaster University Medical Centre, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abadir", 
        "givenName": "A", 
        "id": "sg:person.01150145573.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150145573.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McMaster University Medical Centre, Hamilton, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/grid.411657.0", 
          "name": [
            "McMaster University Medical Centre, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marshall", 
        "givenName": "John K", 
        "id": "sg:person.01267435505.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267435505.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Health, University of Newcastle, Callaghan New South Wales, Australia", 
          "id": "http://www.grid.ac/institutes/grid.266842.c", 
          "name": [
            "Faculty of Health, University of Newcastle, Callaghan New South Wales, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Talley", 
        "givenName": "Nicholas J", 
        "id": "sg:person.0604330074.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604330074.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McMaster University Medical Centre, Hamilton, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/grid.411657.0", 
          "name": [
            "McMaster University Medical Centre, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moayyedi", 
        "givenName": "Paul", 
        "id": "sg:person.01336200702.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336200702.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ajg.2011.58", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012980082", 
          "https://doi.org/10.1038/ajg.2011.58"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2007.01592.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053234582", 
          "https://doi.org/10.1111/j.1572-0241.2007.01592.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2000.01842.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047651520", 
          "https://doi.org/10.1111/j.1572-0241.2000.01842.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1026648812439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038664726", 
          "https://doi.org/10.1023/a:1026648812439"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ajg.2009.315", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002445970", 
          "https://doi.org/10.1038/ajg.2009.315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ajg.2009.29", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027606985", 
          "https://doi.org/10.1038/ajg.2009.29"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10620-007-9760-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018618582", 
          "https://doi.org/10.1007/s10620-007-9760-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08821", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050498034", 
          "https://doi.org/10.1038/nature08821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ajg.2010.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002619249", 
          "https://doi.org/10.1038/ajg.2010.84"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01298873", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027500057", 
          "https://doi.org/10.1007/bf01298873"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-03-15", 
    "datePublishedReg": "2011-03-15", 
    "description": "The etiology of inflammatory bowel disease (IBD) is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. Antibiotics have therefore been proposed as a therapy for Crohn's disease (CD) and ulcerative colitis (UC) to induce remission in active disease to prevent relapse. Current data are conflicting and we therefore conducted a systematic review of randomized controlled trials (RCTs) evaluating antibiotics in IBD. Only parallel group RCTs were considered eligible. Studies with adult patients receiving any dose of therapy for at least 7 days and up to 16 weeks for active disease, or at least 6 months of follow-up for preventing relapse in quiescent disease were analyzed. We included any antibiotics alone or in combination using predefined definitions of remission and relapse. Two reviewers independently assessed eligibility and extracted data. The primary outcome was remission or relapse using an intention-to-treat methodology. The data were summarized using relative risk (RR) and pooled using a random effects model. For active CD, there were 10 RCTs involving 1,160 patients. There was a statistically significant effect of antibiotics being superior to placebo (RR of active CD not in remission=0.85; 95% confidence interval (CI)=0.73-0.99, P=0.03). There was moderate heterogeneity between results (I(2)=48%) and a diverse number of antibiotics were tested (anti-tuberculosis therapy, macrolides, fluroquinolones, 5-nitroimidazoles, and rifaximin) either alone or in combination. Rifamycin derivatives either alone or in combination with other antibiotics appeared to have a significant effect at inducing remission in active CD. In perianal CD fistula there were three trials evaluating 123 patients using either ciprofloxacin or metronidazole. There was a statistically significant effect in reducing fistula drainage (RR=0.8; 95% CI=0.66-0.98) with no heterogeneity (I(2)=0%) and an number needed to treat 5 (95% CI=3-20). For quiescent CD, there were 3 RCTs involving 186 patients treated with different antibiotics combinations (all including antimycobacterials) vs. placebo. There was a statistically significant effect in favor of antibiotics vs. placebo (RR of relapse=0.62; 95% CI=0.46-0.84), with no heterogeneity (I(2)=0%). In active UC, there were 9 RCTs with 662 patients and there was a statistically significant benefit for antibiotics inducing remission (RR of UC not in remission=0.64; 95% CI=0.43-0.96). There was moderate heterogeneity (I(2)=69%) and antibiotics used were all different single or combination drugs. Antibiotic therapy may induce remission in active CD and UC, although the diverse number of antibiotics tested means the data are difficult to interpret. This systematic review is a mandate for further trials of antibiotic therapy in IBD.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/ajg.2011.72", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1412991", 
        "issn": [
          "0002-9270", 
          "1572-0241"
        ], 
        "name": "The American Journal of Gastroenterology", 
        "publisher": "Wolters Kluwer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "106"
      }
    ], 
    "keywords": [
      "inflammatory bowel disease", 
      "active Crohn's disease", 
      "Crohn's disease", 
      "ulcerative colitis", 
      "antibiotic therapy", 
      "systematic review", 
      "active disease", 
      "bowel disease", 
      "relative risk", 
      "moderate heterogeneity", 
      "perianal CD fistulae", 
      "quiescent Crohn's disease", 
      "active ulcerative colitis", 
      "parallel-group RCT", 
      "definition of remission", 
      "dose of therapy", 
      "different antibiotic combinations", 
      "favor of antibiotics", 
      "random-effects model", 
      "CD fistulae", 
      "quiescent disease", 
      "adult patients", 
      "primary outcome", 
      "treat methodology", 
      "group RCT", 
      "fistula drainage", 
      "antibiotic combinations", 
      "remission", 
      "further trials", 
      "combination drugs", 
      "gut microbiota", 
      "patients", 
      "relapse", 
      "RCTs", 
      "Meta-Analysis", 
      "therapy", 
      "immunological reactions", 
      "disease", 
      "rifamycin derivatives", 
      "antibiotics", 
      "significant effect", 
      "trials", 
      "placebo", 
      "bacterial pathogens", 
      "effects model", 
      "current data", 
      "significant benefits", 
      "review", 
      "colitis", 
      "fistula", 
      "etiology", 
      "metronidazole", 
      "dose", 
      "weeks", 
      "months", 
      "drugs", 
      "eligibility", 
      "ciprofloxacin", 
      "outcomes", 
      "microbiota", 
      "effect", 
      "reviewers", 
      "risk", 
      "heterogeneity", 
      "diverse number", 
      "days", 
      "combination", 
      "drainage", 
      "pathogens", 
      "data", 
      "number", 
      "study", 
      "benefits", 
      "favor", 
      "intention", 
      "results", 
      "definition", 
      "reaction", 
      "derivatives", 
      "model", 
      "mandate", 
      "methodology"
    ], 
    "name": "Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis", 
    "pagination": "661", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023776266"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/ajg.2011.72"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21407187"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/ajg.2011.72", 
      "https://app.dimensions.ai/details/publication/pub.1023776266"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_533.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/ajg.2011.72"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/ajg.2011.72'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/ajg.2011.72'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/ajg.2011.72'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/ajg.2011.72'


 

This table displays all metadata directly associated to this object as RDF triples.

292 TRIPLES      21 PREDICATES      129 URIs      111 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/ajg.2011.72 schema:about N0f76c51152d540429b289968309a94a6
2 N1c2ce2f2157349f1a5f9a486c775df7d
3 N20c136d0e23e42a99d18715b2c66a2fb
4 N2c42ebcab0ba4e58ba4563fe3d32d31c
5 N3e1378712fba468f8d21c9c9be77d666
6 N3fe4b95b73f34b0db8af4c8ed3a0dd72
7 N4119a3e023ce4f369ac762b1bdd64e1c
8 N79aa36952daf44b69ce86cd2f940fe0f
9 N82a92091f6d44d0f93ac5239834f6899
10 Nae0a56aa7d7e420388b6eff8e57290c2
11 Nd382e6907f6f44719c759f7a3a77c46d
12 Ne21a2687746b493fa0d8ec3b4c107bc5
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N71ad06e013ef4accb89ce487e6ca0853
16 schema:citation sg:pub.10.1007/bf01298873
17 sg:pub.10.1007/s10620-007-9760-1
18 sg:pub.10.1023/a:1026648812439
19 sg:pub.10.1038/ajg.2009.29
20 sg:pub.10.1038/ajg.2009.315
21 sg:pub.10.1038/ajg.2010.84
22 sg:pub.10.1038/ajg.2011.58
23 sg:pub.10.1038/nature08821
24 sg:pub.10.1111/j.1572-0241.2000.01842.x
25 sg:pub.10.1111/j.1572-0241.2007.01592.x
26 schema:datePublished 2011-03-15
27 schema:datePublishedReg 2011-03-15
28 schema:description The etiology of inflammatory bowel disease (IBD) is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. Antibiotics have therefore been proposed as a therapy for Crohn's disease (CD) and ulcerative colitis (UC) to induce remission in active disease to prevent relapse. Current data are conflicting and we therefore conducted a systematic review of randomized controlled trials (RCTs) evaluating antibiotics in IBD. Only parallel group RCTs were considered eligible. Studies with adult patients receiving any dose of therapy for at least 7 days and up to 16 weeks for active disease, or at least 6 months of follow-up for preventing relapse in quiescent disease were analyzed. We included any antibiotics alone or in combination using predefined definitions of remission and relapse. Two reviewers independently assessed eligibility and extracted data. The primary outcome was remission or relapse using an intention-to-treat methodology. The data were summarized using relative risk (RR) and pooled using a random effects model. For active CD, there were 10 RCTs involving 1,160 patients. There was a statistically significant effect of antibiotics being superior to placebo (RR of active CD not in remission=0.85; 95% confidence interval (CI)=0.73-0.99, P=0.03). There was moderate heterogeneity between results (I(2)=48%) and a diverse number of antibiotics were tested (anti-tuberculosis therapy, macrolides, fluroquinolones, 5-nitroimidazoles, and rifaximin) either alone or in combination. Rifamycin derivatives either alone or in combination with other antibiotics appeared to have a significant effect at inducing remission in active CD. In perianal CD fistula there were three trials evaluating 123 patients using either ciprofloxacin or metronidazole. There was a statistically significant effect in reducing fistula drainage (RR=0.8; 95% CI=0.66-0.98) with no heterogeneity (I(2)=0%) and an number needed to treat 5 (95% CI=3-20). For quiescent CD, there were 3 RCTs involving 186 patients treated with different antibiotics combinations (all including antimycobacterials) vs. placebo. There was a statistically significant effect in favor of antibiotics vs. placebo (RR of relapse=0.62; 95% CI=0.46-0.84), with no heterogeneity (I(2)=0%). In active UC, there were 9 RCTs with 662 patients and there was a statistically significant benefit for antibiotics inducing remission (RR of UC not in remission=0.64; 95% CI=0.43-0.96). There was moderate heterogeneity (I(2)=69%) and antibiotics used were all different single or combination drugs. Antibiotic therapy may induce remission in active CD and UC, although the diverse number of antibiotics tested means the data are difficult to interpret. This systematic review is a mandate for further trials of antibiotic therapy in IBD.
29 schema:genre article
30 schema:isAccessibleForFree false
31 schema:isPartOf N97605d4dcc064e20a689a9cddfc4a7a0
32 Ne24c4e0af1a8429da5716a262afd4d17
33 sg:journal.1412991
34 schema:keywords CD fistulae
35 Crohn's disease
36 Meta-Analysis
37 RCTs
38 active Crohn's disease
39 active disease
40 active ulcerative colitis
41 adult patients
42 antibiotic combinations
43 antibiotic therapy
44 antibiotics
45 bacterial pathogens
46 benefits
47 bowel disease
48 ciprofloxacin
49 colitis
50 combination
51 combination drugs
52 current data
53 data
54 days
55 definition
56 definition of remission
57 derivatives
58 different antibiotic combinations
59 disease
60 diverse number
61 dose
62 dose of therapy
63 drainage
64 drugs
65 effect
66 effects model
67 eligibility
68 etiology
69 favor
70 favor of antibiotics
71 fistula
72 fistula drainage
73 further trials
74 group RCT
75 gut microbiota
76 heterogeneity
77 immunological reactions
78 inflammatory bowel disease
79 intention
80 mandate
81 methodology
82 metronidazole
83 microbiota
84 model
85 moderate heterogeneity
86 months
87 number
88 outcomes
89 parallel-group RCT
90 pathogens
91 patients
92 perianal CD fistulae
93 placebo
94 primary outcome
95 quiescent Crohn's disease
96 quiescent disease
97 random-effects model
98 reaction
99 relapse
100 relative risk
101 remission
102 results
103 review
104 reviewers
105 rifamycin derivatives
106 risk
107 significant benefits
108 significant effect
109 study
110 systematic review
111 therapy
112 treat methodology
113 trials
114 ulcerative colitis
115 weeks
116 schema:name Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
117 schema:pagination 661
118 schema:productId N72307adab44040ecb3ea7b11af69175a
119 Na3499aec1c5a4a9b83d687a53b164bdb
120 Nf71398070d8e44e785f2c1036ed0e47a
121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023776266
122 https://doi.org/10.1038/ajg.2011.72
123 schema:sdDatePublished 2022-10-01T06:36
124 schema:sdLicense https://scigraph.springernature.com/explorer/license/
125 schema:sdPublisher Nd3cafb08459f40bdb28344f2c3dd1619
126 schema:url https://doi.org/10.1038/ajg.2011.72
127 sgo:license sg:explorer/license/
128 sgo:sdDataset articles
129 rdf:type schema:ScholarlyArticle
130 N0f76c51152d540429b289968309a94a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Randomized Controlled Trials as Topic
132 rdf:type schema:DefinedTerm
133 N1c2ce2f2157349f1a5f9a486c775df7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Remission Induction
135 rdf:type schema:DefinedTerm
136 N20c136d0e23e42a99d18715b2c66a2fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Secondary Prevention
138 rdf:type schema:DefinedTerm
139 N2c42ebcab0ba4e58ba4563fe3d32d31c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Drug Combinations
141 rdf:type schema:DefinedTerm
142 N3e1378712fba468f8d21c9c9be77d666 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Colitis, Ulcerative
144 rdf:type schema:DefinedTerm
145 N3fe4b95b73f34b0db8af4c8ed3a0dd72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Risk
147 rdf:type schema:DefinedTerm
148 N4119a3e023ce4f369ac762b1bdd64e1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Crohn Disease
150 rdf:type schema:DefinedTerm
151 N46da87a973b640189e4c54b1c69c544a rdf:first sg:person.0606477677.70
152 rdf:rest N7bdda2b276994dd3beba7c3a62bf24ce
153 N5e2435156f7940c4a591bb1e807a4ade rdf:first sg:person.01336200702.64
154 rdf:rest rdf:nil
155 N71ad06e013ef4accb89ce487e6ca0853 rdf:first sg:person.0722775106.31
156 rdf:rest N8ac525bf104a47fa985cbd4993bbad28
157 N72307adab44040ecb3ea7b11af69175a schema:name dimensions_id
158 schema:value pub.1023776266
159 rdf:type schema:PropertyValue
160 N79aa36952daf44b69ce86cd2f940fe0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Rifamycins
162 rdf:type schema:DefinedTerm
163 N7bdda2b276994dd3beba7c3a62bf24ce rdf:first sg:person.01150145573.40
164 rdf:rest Ne97f0d71f14544eca0e7c1050f4580ff
165 N82a92091f6d44d0f93ac5239834f6899 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Treatment Outcome
167 rdf:type schema:DefinedTerm
168 N8ac525bf104a47fa985cbd4993bbad28 rdf:first sg:person.01031655740.00
169 rdf:rest Ncf184d7b188747e5a4b118af13452ff3
170 N97605d4dcc064e20a689a9cddfc4a7a0 schema:issueNumber 4
171 rdf:type schema:PublicationIssue
172 Na3499aec1c5a4a9b83d687a53b164bdb schema:name pubmed_id
173 schema:value 21407187
174 rdf:type schema:PropertyValue
175 Nae0a56aa7d7e420388b6eff8e57290c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Anti-Bacterial Agents
177 rdf:type schema:DefinedTerm
178 Ncf184d7b188747e5a4b118af13452ff3 rdf:first sg:person.01251421433.66
179 rdf:rest N46da87a973b640189e4c54b1c69c544a
180 Nd382e6907f6f44719c759f7a3a77c46d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Severity of Illness Index
182 rdf:type schema:DefinedTerm
183 Nd3cafb08459f40bdb28344f2c3dd1619 schema:name Springer Nature - SN SciGraph project
184 rdf:type schema:Organization
185 Ne21a2687746b493fa0d8ec3b4c107bc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Humans
187 rdf:type schema:DefinedTerm
188 Ne24c4e0af1a8429da5716a262afd4d17 schema:volumeNumber 106
189 rdf:type schema:PublicationVolume
190 Ne78d44972a8947bd8a4dfd200957a2f9 rdf:first sg:person.0604330074.20
191 rdf:rest N5e2435156f7940c4a591bb1e807a4ade
192 Ne97f0d71f14544eca0e7c1050f4580ff rdf:first sg:person.01267435505.42
193 rdf:rest Ne78d44972a8947bd8a4dfd200957a2f9
194 Nf71398070d8e44e785f2c1036ed0e47a schema:name doi
195 schema:value 10.1038/ajg.2011.72
196 rdf:type schema:PropertyValue
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
201 schema:name Clinical Sciences
202 rdf:type schema:DefinedTerm
203 sg:journal.1412991 schema:issn 0002-9270
204 1572-0241
205 schema:name The American Journal of Gastroenterology
206 schema:publisher Wolters Kluwer
207 rdf:type schema:Periodical
208 sg:person.01031655740.00 schema:affiliation grid-institutes:grid.59734.3c
209 schema:familyName Ullman
210 schema:givenName Thomas A
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031655740.00
212 rdf:type schema:Person
213 sg:person.01150145573.40 schema:affiliation grid-institutes:grid.411657.0
214 schema:familyName Abadir
215 schema:givenName A
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150145573.40
217 rdf:type schema:Person
218 sg:person.01251421433.66 schema:affiliation grid-institutes:grid.418161.b
219 schema:familyName Ford
220 schema:givenName Alexander C
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251421433.66
222 rdf:type schema:Person
223 sg:person.01267435505.42 schema:affiliation grid-institutes:grid.411657.0
224 schema:familyName Marshall
225 schema:givenName John K
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267435505.42
227 rdf:type schema:Person
228 sg:person.01336200702.64 schema:affiliation grid-institutes:grid.411657.0
229 schema:familyName Moayyedi
230 schema:givenName Paul
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336200702.64
232 rdf:type schema:Person
233 sg:person.0604330074.20 schema:affiliation grid-institutes:grid.266842.c
234 schema:familyName Talley
235 schema:givenName Nicholas J
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604330074.20
237 rdf:type schema:Person
238 sg:person.0606477677.70 schema:affiliation grid-institutes:grid.26790.3a
239 schema:familyName Abreu
240 schema:givenName Maria T
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606477677.70
242 rdf:type schema:Person
243 sg:person.0722775106.31 schema:affiliation grid-institutes:grid.411657.0
244 schema:familyName Khan
245 schema:givenName Khurram J
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722775106.31
247 rdf:type schema:Person
248 sg:pub.10.1007/bf01298873 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027500057
249 https://doi.org/10.1007/bf01298873
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s10620-007-9760-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018618582
252 https://doi.org/10.1007/s10620-007-9760-1
253 rdf:type schema:CreativeWork
254 sg:pub.10.1023/a:1026648812439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038664726
255 https://doi.org/10.1023/a:1026648812439
256 rdf:type schema:CreativeWork
257 sg:pub.10.1038/ajg.2009.29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027606985
258 https://doi.org/10.1038/ajg.2009.29
259 rdf:type schema:CreativeWork
260 sg:pub.10.1038/ajg.2009.315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002445970
261 https://doi.org/10.1038/ajg.2009.315
262 rdf:type schema:CreativeWork
263 sg:pub.10.1038/ajg.2010.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002619249
264 https://doi.org/10.1038/ajg.2010.84
265 rdf:type schema:CreativeWork
266 sg:pub.10.1038/ajg.2011.58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012980082
267 https://doi.org/10.1038/ajg.2011.58
268 rdf:type schema:CreativeWork
269 sg:pub.10.1038/nature08821 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050498034
270 https://doi.org/10.1038/nature08821
271 rdf:type schema:CreativeWork
272 sg:pub.10.1111/j.1572-0241.2000.01842.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047651520
273 https://doi.org/10.1111/j.1572-0241.2000.01842.x
274 rdf:type schema:CreativeWork
275 sg:pub.10.1111/j.1572-0241.2007.01592.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1053234582
276 https://doi.org/10.1111/j.1572-0241.2007.01592.x
277 rdf:type schema:CreativeWork
278 grid-institutes:grid.266842.c schema:alternateName Faculty of Health, University of Newcastle, Callaghan New South Wales, Australia
279 schema:name Faculty of Health, University of Newcastle, Callaghan New South Wales, Australia
280 rdf:type schema:Organization
281 grid-institutes:grid.26790.3a schema:alternateName Miller School of Medicine, University of Miami, Miami, Florida, USA
282 schema:name Miller School of Medicine, University of Miami, Miami, Florida, USA
283 rdf:type schema:Organization
284 grid-institutes:grid.411657.0 schema:alternateName McMaster University Medical Centre, Hamilton, Ontario, Canada
285 schema:name McMaster University Medical Centre, Hamilton, Ontario, Canada
286 rdf:type schema:Organization
287 grid-institutes:grid.418161.b schema:alternateName Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
288 schema:name Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
289 rdf:type schema:Organization
290 grid-institutes:grid.59734.3c schema:alternateName The Mount Sinai School of Medicine, New York, New York, USA
291 schema:name The Mount Sinai School of Medicine, New York, New York, USA
292 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...